KNBIF (Kane Biotech) Long-Term Debt: $0.47 Mil (As of Mar. 2026)


What is Kane Biotech Long-Term Debt?

Kane Biotech KNBIF -1.86% Long-Term Debt is $0.47 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Kane Biotech's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.47 Mil.

Kane Biotech's quarterly Long-Term Debt declined from Sep. 2025 ($1.21 Mil) to Dec. 2025 ($0.45 Mil) but then increased from Dec. 2025 ($0.45 Mil) to Mar. 2026 ($0.47 Mil).

Kane Biotech's annual Long-Term Debt declined from Dec. 2023 ($0.97 Mil) to Dec. 2024 ($0.67 Mil) and declined from Dec. 2024 ($0.67 Mil) to Dec. 2025 ($0.45 Mil).

Kane Biotech  (OTCPK:KNBIF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Kane Biotech Long-Term Debt Related Terms

Kane Biotech Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Kane Biotech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech Long-Term Debt Chart

Kane Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 1.17 0.97 0.67 0.45

Kane Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 1.00 1.21 0.45 0.47
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.47 Mil mean?
Kane Biotech (KNBIF) has a Long-Term Debt of $0.47 Mil as of Mar. 2026.
Is Kane Biotech's Long-Term Debt too high?
Kane Biotech's current Long-Term Debt is $0.47 Mil.
How does Kane Biotech's Long-Term Debt compare to VRTX and REGN?
Kane Biotech's Long-Term Debt of $0.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Kane Biotech's current Long-Term Debt is $0.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Long-Term Debt of $0.47 Mil. The current Long-Term Debt is $0.47 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Long-Term Debt is $0.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.